Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 71,946

Sort by:

Calcium-Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium-Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Calcium/Calmo...

May 2022 39 pages

Calcium Release Activated Calcium Channel Protein 1 (Protein Orai 1 or Transmembrane Protein 142A or ORAI1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium Release Activated Calcium Channel Protein 1 (Protein Orai 1 or Transmembrane Protein 142A or ORAI1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and K...

May 2022 41 pages

Calcium Sensing Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium Sensing Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Calcium Sensing Receptor Drugs in Development by Therapy Areas a...

May 2022 40 pages

Calreticulin (Calregulin or Endoplasmic Reticulum Resident Protein 60 or CRP55 or HACBP or grp60 or CALR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calreticulin (Calregulin or Endoplasmic Reticulum Resident Protein 60 or CRP55 or HACBP or grp60 or CALR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 39 pages

cAMP Specific 3,5 Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B or EC 3.1.4.53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

cAMP Specific 3,5 Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B or EC 3.1.4.53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY cA...

May 2022 36 pages

Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy Areas and Indicat...

May 2022 48 pages

Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cannabinoid Receptor 1 (CB1 or CANN6 or CNR...

May 2022 298 pages

Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) D...

May 2022 292 pages

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54-58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54-58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) Drugs in Development by Therapy Areas and...

May 2022 40 pages

Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and...

May 2022 54 pages

Carcinoembryonic Antigen (CEA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carcinoembryonic Antigen (CEA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Carcinoembryonic Antigen (CEA) Drugs in Development by The...

May 2022 51 pages

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indications, Stages, M...

May 2022 38 pages

Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 40 pages

Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 266 pages

Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 47 pages

Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...

May 2022 122 pages

Cardiovascular Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cardiovascular Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cardiovascular Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 76 pages

Carotid Artery Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Carotid Artery Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Carotid Artery Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 35 pages

Cartilage Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cartilage Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cartilage Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 43 pages

Casein Kinase 2 (CSNK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Casein Kinase 2 (CSNK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Casein Kinase 2 (CSNK2 or EC 2.7.11.1) Drugs in De...

May 2022 40 pages

Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Casein Kinase...

May 2022 37 pages

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type a...

May 2022 37 pages

Caspase 1 (Interleukin 1 Beta Convertase or Interleukin 1 Beta Converting Enzyme or p45 or CASP1 or EC 3.4.22.36) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Caspase 1 (Interleukin 1 Beta Convertase or Interleukin 1 Beta Converting Enzyme or p45 or CASP1 or EC 3.4.22.36) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 39 pages

Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy...

May 2022 66 pages

CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY CD27...

May 2022 35 pages

CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 or CD44) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or P...

May 2022 37 pages

Cells Expressing ADP Ribosyl Cyclase-Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2 Phospho ADP Ribosyl Cyclase-2 Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing ADP Ribosyl Cyclase-Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2 Phospho ADP Ribosyl Cyclase-2 Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase...

May 2022 86 pages

Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 35 pages

Cells Expressing Alpha Fetoprotein (Alpha 1 Fetoprotein or Alpha Fetoglobulin or AFP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Alpha Fetoprotein (Alpha 1 Fetoprotein or Alpha Fetoglobulin or AFP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cel...

May 2022 40 pages

Cells Expressing Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy...

May 2022 74 pages

Cells Expressing CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pla...

May 2022 73 pages

Cells Expressing CD3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing CD3 Drugs in Development by Therapy Areas and Indic...

May 2022 39 pages

Cells Expressing CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 or CD44) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluron...

May 2022 39 pages

Cells Expressing CD70 Antigen (CD27 Ligand or Tumor Necrosis Factor Ligand Superfamily Member 7 or CD70) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD70 Antigen (CD27 Ligand or Tumor Necrosis Factor Ligand Superfamily Member 7 or CD70) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 42 pages

Cells Expressing Claudin 18 (CLDN18) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Claudin 18 (CLDN18) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Claudin 18 (CLDN18) Drugs in Develo...

May 2022 82 pages

Cells Expressing Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 36 pages

Cells Expressing Delta Like Protein 3 (Drosophila Delta Homolog 3 or DLL3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Delta Like Protein 3 (Drosophila Delta Homolog 3 or DLL3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressi...

May 2022 40 pages

Cells Expressing Folate Receptor (FOLR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Folate Receptor (FOLR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Folate Receptor (FOLR) Drugs in...

May 2022 35 pages

Cells Expressing Glypican 3 (Heparan Sulphate Proteoglycan or Intestinal Protein OCI 5 or GTR2 2 or MXR7 or GPC3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Glypican 3 (Heparan Sulphate Proteoglycan or Intestinal Protein OCI 5 or GTR2 2 or MXR7 or GPC3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 84 pages

Cells Expressing GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Ex...

May 2022 43 pages

Cells Expressing Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by The...

May 2022 41 pages

Cells Expressing Human Papillomavirus Protein E7 (E7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Human Papillomavirus Protein E7 (E7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Human Papillomavir...

May 2022 37 pages

Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Ce...

May 2022 35 pages

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY C...

May 2022 40 pages

Cells Expressing Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY C...

May 2022 36 pages

Cells Expressing Interleukin 13 Receptor Subunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Interleukin 13 Receptor Subunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type a...

May 2022 48 pages

Cells Expressing Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMA...

May 2022 43 pages

Cells Expressing Interleukin 3 Receptor Subunit Alpha (CD123 or IL3RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Interleukin 3 Receptor Subunit Alpha (CD123 or IL3RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing I...

May 2022 77 pages

Cells Expressing Latent Membrane Protein 1 (Protein p63 or LMP1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Latent Membrane Protein 1 (Protein p63 or LMP1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Latent...

May 2022 38 pages

Cells Expressing Latent Membrane Protein 2 (Terminal Protein or LMP2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Latent Membrane Protein 2 (Terminal Protein or LMP2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing La...

May 2022 37 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

33% OFF on “TCR-Based Antibody a...

Discount Offer from GMD Research

280

Special Offer from MP Advisors

Special Offer on Therapy Class R...